{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:00:45Z","timestamp":1781254845595,"version":"3.54.1"},"reference-count":55,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s599644","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:45:11Z","timestamp":1781253911000},"page":"1-14","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-5251","authenticated-orcid":true,"given":"Gianni","family":"Ghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linet","family":"Odonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"De Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Marchionne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6]]},"reference":[{"key":"ref1","unstructured":"Leukaemia Foundation. Acute lymphoblastic leukaemia (ALL). Available from: https:\/\/www.leukaemia.org.au\/blood-cancer\/types-of-blood-cancer\/leukaemia\/acute-lymphoblastic-leukaemia\/. Accessed June 9, 2025."},{"key":"ref2","unstructured":"European Society for Medical Oncology. Clinical Practice Guideline: Acute Lymphoblastic Leukaemia | ESMO. Available from: https:\/\/www.esmo.org\/guidelines\/esmo-clinical-practice-guideline-acute-lymphoblastic-leukaemia. Accessed June 9, 2025."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"ref4","unstructured":"Shilpa P, Hagop K, Jabbour EJ. Adult acute lymphoblastic leukemia. Available from: https:\/\/www.mayoclinicproceedings.org\/article\/S0025-6196(16)30584-5\/pdf. Accessed June 13, 2025."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"key":"ref8","unstructured":"European Medicines Agency. Blincyto. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/blincyto. Accessed June 10, 2025."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"National Institute for Health and Care Excellence. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | guidance | TA1049. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1049. Accessed June 19, 2025."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","volume":"7","author":"Bassan","year":"2023","journal-title":"Blood Adv"},{"key":"ref12","unstructured":"Piciocchi A, Marsili G, Messina M, et al. Comparative efficacy of the GIMEMA LAL1913 standard chemotherapy protocol versus the standard arm of the E1910 trial in MRD-negative Ph-negative ALL: a MAIC analysis. Present EHA 2025. Available from: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4160455\/. Accessed June 18, 2025."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s12325-019-01099-x","volume":"36","author":"Gidman","year":"2019","journal-title":"Adv Ther"},{"key":"ref14","unstructured":"AIFA. Linee guida AIFA per la compilazione del dossier a supporto della domanda di rimborsabilit\u00e0 e prezzo di un medicinale."},{"key":"ref15","unstructured":"Codifa - L\u2019Informatore Farmaceutico. Available from: https:\/\/www.codifa.it\/. Accessed April 22, 2024."},{"key":"ref16","unstructured":"Ministero della salute. Remunerazione prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Decreto 10\/2012 pubblicato in GU Serie Generale n.23 del 28-1-2013. 2013."},{"key":"ref17","unstructured":"Regione Lombardia. DELIBERAZIONE N\u00b0 IX \/ 2946; 2012."},{"key":"ref18","unstructured":"Ministero della Salute. Definizione delle tariffe relative all\u2019assistenza specialistica ambulatoriale e protesica. Decreto 11\/2024 pubblicato in GU Serie Generale n.302 del 27-12-2024; 2024."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1182\/blood.V130.Suppl_1.5488","volume":"130","author":"Lupo Stanghellini","year":"2019","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"ckw152","DOI":"10.1093\/eurpub\/ckw152","author":"Scaccabarozzi","year":"2016","journal-title":"Eur J Public Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.11098","volume":"97","author":"Sung","year":"2003","journal-title":"Cancer"},{"key":"ref24","unstructured":"Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU TECHNICAL SUPPORT DOCUMENT 21."},{"key":"ref25","unstructured":"Italian National Institute of Statistics. Demographic Statistics in Italy. Available from: https:\/\/demo.istat.it\/. Accessed June 18, 2025."},{"key":"ref26","unstructured":"National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25\u202fyears and under. Available from: https:\/\/www.nice.org.uk\/guidance\/ta975\/chapter\/1-Recommendations. Accessed June 12, 2025."},{"key":"ref27","unstructured":"National Institute for Health and Care Excellence. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. Available from: https:\/\/www.nice.org.uk\/guidance\/ta893\/documents\/129. Accessed June 12, 2025."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"ref29","unstructured":"Jordan A. Flexsurvcure: flexible parametric cure models 2025. Available from: https:\/\/cran.r-project.org\/web\/packages\/flexsurvcure\/flexsurvcure.pdf. Accessed June 10, 2025."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jval.2013.04.008","volume":"16","author":"Scalone","year":"2013","journal-title":"Value Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2427\/11457","volume":"12","author":"Scalone","year":"2022","journal-title":"Epidemiol Biostat Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/CEOR.S41850","author":"Lazzaro","year":"2013","journal-title":"Clin Outcomes Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjc.6605417","volume":"102","author":"Mickisch","year":"2010","journal-title":"Br J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","volume":"41","author":"Russo","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1182\/blood.2024027500","volume":"145","author":"Bassan","year":"2025","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/13696998.2017.1344127","volume":"20","author":"Delea","year":"2017","journal-title":"J Med Econ"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s41669-023-00411-4","volume":"7","author":"Caillon","year":"2023","journal-title":"PharmacoEconomics - Open"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"107560","DOI":"10.1016\/j.leukres.2024.107560","volume":"145","author":"Diaz martinez","year":"2024","journal-title":"Leuk Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40273-022-01188-w","volume":"41","author":"Gye","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"241.e1","DOI":"10.1016\/j.jtct.2020.12.023","volume":"27","author":"Wakase","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","volume":"25","author":"Neumann","year":"2022","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1185\/03007991003712258","volume":"26","author":"Swinburn","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s41669-021-00316-0","volume":"6","author":"Howell","year":"2022","journal-title":"PharmacoEconomics - Open"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"ref49","unstructured":"National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. Technology appraisal guidance Reference number: TA510. Available from: https:\/\/www.nice.org.uk\/guidance\/ta510. Accessed June 20, 2025."},{"key":"ref50","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. Technology appraisal guidance TA520. Available from: https:\/\/www.nice.org.uk\/guidance\/ta520. Accessed June 20, 2025."},{"key":"ref51","unstructured":"National Institute for Health and Care Excellence. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer. Technology appraisal guidance Reference number: TA416. Available from: https:\/\/www.nice.org.uk\/guidance\/ta416. Accessed June 20, 2025."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"Tolley","year":"2013","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"key":"ref53","unstructured":"National Institute for Health and Care Excellence. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. Technology appraisal guidance Reference number: TA642. Available from: https:\/\/www.nice.org.uk\/guidance\/ta642. Accessed June 20, 2025."},{"key":"ref54","unstructured":"National Institute for Health and Care Excellence. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Technology appraisal guidance. Reference number: TA541. Available from: https:\/\/www.nice.org.uk\/guidance\/ta541. Accessed June 20, 2025."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/116317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/116317","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:45:29Z","timestamp":1781253929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cost-effectiveness-of-blinatumomab-plus-chemotherapy-vs-chemotherapy-i-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"URL":"https:\/\/doi.org\/10.2147\/ceor.s599644","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}